NEW YORK (GenomeWeb) – Vela Diagnostics has submitted a next-generation sequencing assay that detects HIV-1 drug resistance mutations (DRMs) to the US Food and Drug Administration, the company announced today.

The Sentosa SQ HIV Genotyping Assay can be used on plasma samples from patients with HIV-1 infection to detect HIV-1 Group M genomic DRMs in the protease, reverse transcriptase, and integrase regions of the pol gene. Resistance to antiretroviral drugs as a result of DRMs is the most common cause of therapeutic failure in HIV treatment.